Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC Lung Cancer Working Party (Belgium).

Abstract

The current study reports the results of Adriamycin (doxorubicin), etoposide, and cyclophosphamide (AVE) in small cell bronchogenic carcinoma. The overall rate of response was 82% in patients with limited disease and 66% in patients with extensive disease; complete remissions have been achieved in 20% of the patients with limited disease and in 7% of those with extensive disease. The median duration of survival was 14 months in patients with limited disease and 8.3 months in those with extensive disease. The results, and the analysis of literature, suggest that survival rather than response should be used to compare studies of chemotherapy in small cell bronchogenic carcinoma.

• Authors: J Klastersky, J P Sculier, J P Dumont, D Becquart, G Vandermoten, P Rocmans, J Michel, E Longeval, O Dalesio
• Journal: Cancer (Cancer) Vol. 56 Issue 1 Pg. 71-5 (Jul 01 1985) ISSN: 0008-543X [Print] United States
• PMID: 2988738 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Etoposide
• Doxorubicin
• Cyclophosphamide

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Belgium
• Carcinoma, Bronchogenic (drug therapy, pathology)
• Carcinoma, Small Cell (drug therapy, pathology)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Follow-Up Studies
• Hematologic Diseases (chemically induced)
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Male
• Middle Aged